Miguel Hernan, D.P.H., M.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Causality | 12 | 2024 | 1252 | 2.080 |
Why?
|
| Epidemiologic Research Design | 6 | 2016 | 368 | 1.330 |
Why?
|
| Observation | 5 | 2012 | 310 | 1.290 |
Why?
|
| Epidemiologic Studies | 5 | 2016 | 677 | 1.190 |
Why?
|
| Comparative Effectiveness Research | 4 | 2016 | 713 | 0.900 |
Why?
|
| Selection Bias | 5 | 2016 | 359 | 0.800 |
Why?
|
| Randomized Controlled Trials as Topic | 8 | 2012 | 10384 | 0.590 |
Why?
|
| Parkinson Disease | 6 | 2006 | 2884 | 0.480 |
Why?
|
| Hepatitis B Vaccines | 2 | 2006 | 178 | 0.460 |
Why?
|
| Smoking | 7 | 2008 | 9077 | 0.420 |
Why?
|
| Antiretroviral Therapy, Highly Active | 4 | 2015 | 1900 | 0.420 |
Why?
|
| Epidemiologic Methods | 3 | 2009 | 1326 | 0.410 |
Why?
|
| Multiple Sclerosis | 5 | 2006 | 3229 | 0.390 |
Why?
|
| Oseltamivir | 1 | 2011 | 76 | 0.360 |
Why?
|
| Data Interpretation, Statistical | 3 | 2011 | 2693 | 0.350 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 2 | 2018 | 3250 | 0.350 |
Why?
|
| Intention to Treat Analysis | 1 | 2011 | 418 | 0.350 |
Why?
|
| Water | 1 | 2016 | 1417 | 0.340 |
Why?
|
| AIDS Dementia Complex | 2 | 2015 | 154 | 0.340 |
Why?
|
| Multicenter Studies as Topic | 2 | 2013 | 1733 | 0.340 |
Why?
|
| Tetanus Toxoid | 2 | 2006 | 188 | 0.310 |
Why?
|
| Pneumonia, Bacterial | 1 | 2011 | 319 | 0.300 |
Why?
|
| Coronary Disease | 2 | 2012 | 5915 | 0.280 |
Why?
|
| Pharmacoepidemiology | 1 | 2008 | 351 | 0.240 |
Why?
|
| Proportional Hazards Models | 5 | 2011 | 12534 | 0.220 |
Why?
|
| Leisure Activities | 1 | 2005 | 310 | 0.220 |
Why?
|
| Central Nervous System | 2 | 2015 | 1345 | 0.210 |
Why?
|
| Models, Statistical | 6 | 2024 | 5091 | 0.200 |
Why?
|
| Estrogen Replacement Therapy | 1 | 2008 | 1205 | 0.200 |
Why?
|
| Monoamine Oxidase | 1 | 2002 | 179 | 0.190 |
Why?
|
| Life Expectancy | 1 | 2008 | 1249 | 0.190 |
Why?
|
| Anti-Retroviral Agents | 1 | 2011 | 1787 | 0.190 |
Why?
|
| Anti-HIV Agents | 3 | 2015 | 4562 | 0.180 |
Why?
|
| Body Mass Index | 2 | 2009 | 13050 | 0.180 |
Why?
|
| HIV Infections | 4 | 2011 | 17536 | 0.180 |
Why?
|
| Zidovudine | 1 | 2002 | 625 | 0.170 |
Why?
|
| Catechol O-Methyltransferase | 1 | 2002 | 250 | 0.170 |
Why?
|
| Influenza, Human | 1 | 2011 | 1543 | 0.170 |
Why?
|
| Policy | 1 | 2023 | 512 | 0.160 |
Why?
|
| Neural Tube Defects | 1 | 2002 | 256 | 0.160 |
Why?
|
| Multiple Sclerosis, Relapsing-Remitting | 1 | 2005 | 551 | 0.160 |
Why?
|
| Contraceptives, Oral, Hormonal | 1 | 2000 | 187 | 0.160 |
Why?
|
| HIV-1 | 2 | 2010 | 6948 | 0.160 |
Why?
|
| Antiviral Agents | 1 | 2011 | 3070 | 0.150 |
Why?
|
| Mendelian Randomization Analysis | 1 | 2024 | 1044 | 0.150 |
Why?
|
| Coffee | 1 | 2002 | 594 | 0.150 |
Why?
|
| CD4 Lymphocyte Count | 3 | 2011 | 2586 | 0.150 |
Why?
|
| Longitudinal Studies | 3 | 2008 | 14762 | 0.140 |
Why?
|
| Humans | 40 | 2024 | 766766 | 0.140 |
Why?
|
| Vaccination | 2 | 2006 | 3434 | 0.140 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2006 | 2270 | 0.130 |
Why?
|
| Activities of Daily Living | 1 | 2005 | 2429 | 0.130 |
Why?
|
| Odds Ratio | 5 | 2008 | 9661 | 0.130 |
Why?
|
| Body Composition | 1 | 2005 | 2441 | 0.130 |
Why?
|
| Databases, Factual | 3 | 2021 | 8066 | 0.120 |
Why?
|
| Folic Acid | 1 | 2002 | 1337 | 0.120 |
Why?
|
| Time Factors | 7 | 2016 | 40149 | 0.110 |
Why?
|
| Alcohol Drinking | 2 | 2024 | 4045 | 0.110 |
Why?
|
| Alcoholism | 1 | 2004 | 1980 | 0.110 |
Why?
|
| Dementia | 1 | 2008 | 2741 | 0.110 |
Why?
|
| Risk Assessment | 4 | 2011 | 24295 | 0.100 |
Why?
|
| Case-Control Studies | 6 | 2006 | 22248 | 0.100 |
Why?
|
| Drug Administration Schedule | 2 | 2011 | 4853 | 0.100 |
Why?
|
| Health Status | 1 | 2005 | 4087 | 0.100 |
Why?
|
| Prospective Studies | 9 | 2011 | 54871 | 0.100 |
Why?
|
| Polymorphism, Genetic | 1 | 2002 | 4249 | 0.100 |
Why?
|
| Referral and Consultation | 1 | 2023 | 3618 | 0.090 |
Why?
|
| Drug Therapy, Combination | 2 | 2011 | 6307 | 0.090 |
Why?
|
| Female | 20 | 2016 | 396520 | 0.090 |
Why?
|
| Decision Making | 2 | 2016 | 3951 | 0.090 |
Why?
|
| Research Design | 3 | 2016 | 6207 | 0.080 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2002 | 4410 | 0.080 |
Why?
|
| Neoplasms | 1 | 2018 | 22350 | 0.080 |
Why?
|
| Male | 17 | 2016 | 364142 | 0.080 |
Why?
|
| Research Support as Topic | 1 | 2013 | 697 | 0.080 |
Why?
|
| Exercise | 1 | 2005 | 5945 | 0.080 |
Why?
|
| Product Surveillance, Postmarketing | 1 | 2013 | 463 | 0.080 |
Why?
|
| Incidence | 5 | 2006 | 21525 | 0.070 |
Why?
|
| Developed Countries | 1 | 2011 | 452 | 0.070 |
Why?
|
| Middle Aged | 13 | 2011 | 223257 | 0.070 |
Why?
|
| Controlled Clinical Trials as Topic | 1 | 2008 | 187 | 0.070 |
Why?
|
| Estrogens, Conjugated (USP) | 1 | 2008 | 274 | 0.070 |
Why?
|
| Progestins | 1 | 2008 | 300 | 0.070 |
Why?
|
| Aging | 1 | 2005 | 8731 | 0.070 |
Why?
|
| Cohort Studies | 6 | 2006 | 41710 | 0.060 |
Why?
|
| Obesity | 1 | 2008 | 13090 | 0.060 |
Why?
|
| Sensitivity and Specificity | 2 | 2011 | 14652 | 0.060 |
Why?
|
| Secondary Prevention | 1 | 2012 | 1469 | 0.060 |
Why?
|
| Medical Records Systems, Computerized | 1 | 2011 | 1196 | 0.060 |
Why?
|
| Antiparkinson Agents | 1 | 2006 | 184 | 0.060 |
Why?
|
| Cardiovascular Diseases | 2 | 2024 | 15657 | 0.060 |
Why?
|
| Risk Factors | 7 | 2006 | 74881 | 0.060 |
Why?
|
| Tremor | 1 | 2006 | 196 | 0.060 |
Why?
|
| Aged | 9 | 2011 | 171343 | 0.060 |
Why?
|
| Primary Prevention | 1 | 2012 | 1188 | 0.060 |
Why?
|
| Stochastic Processes | 1 | 2005 | 359 | 0.060 |
Why?
|
| Sex Characteristics | 2 | 2006 | 2645 | 0.050 |
Why?
|
| Risk | 2 | 2006 | 9602 | 0.050 |
Why?
|
| Adult | 10 | 2011 | 223307 | 0.050 |
Why?
|
| United States | 6 | 2013 | 72951 | 0.050 |
Why?
|
| Family Practice | 1 | 2006 | 508 | 0.050 |
Why?
|
| Beer | 1 | 2003 | 135 | 0.050 |
Why?
|
| Population | 1 | 2003 | 140 | 0.050 |
Why?
|
| Europe | 1 | 2010 | 3430 | 0.050 |
Why?
|
| Wine | 1 | 2003 | 172 | 0.050 |
Why?
|
| Research Subjects | 1 | 2004 | 248 | 0.050 |
Why?
|
| Multiple Sclerosis, Chronic Progressive | 1 | 2005 | 253 | 0.050 |
Why?
|
| Acquired Immunodeficiency Syndrome | 1 | 2011 | 2205 | 0.050 |
Why?
|
| Evaluation Studies as Topic | 1 | 2004 | 1622 | 0.050 |
Why?
|
| Acetaminophen | 1 | 2006 | 549 | 0.050 |
Why?
|
| Vaccines, Synthetic | 1 | 2004 | 620 | 0.050 |
Why?
|
| Estrogens | 1 | 2008 | 1528 | 0.050 |
Why?
|
| California | 1 | 2005 | 1435 | 0.050 |
Why?
|
| Disease Progression | 2 | 2011 | 13640 | 0.050 |
Why?
|
| Electric Impedance | 1 | 2005 | 791 | 0.050 |
Why?
|
| Ontario | 1 | 2002 | 404 | 0.050 |
Why?
|
| Probability | 1 | 2006 | 2476 | 0.050 |
Why?
|
| Anthropometry | 1 | 2005 | 1336 | 0.040 |
Why?
|
| Longevity | 1 | 2008 | 1083 | 0.040 |
Why?
|
| Viral Load | 1 | 2010 | 3385 | 0.040 |
Why?
|
| Cause of Death | 1 | 2011 | 3716 | 0.040 |
Why?
|
| Medication Adherence | 1 | 2012 | 2190 | 0.040 |
Why?
|
| Absorptiometry, Photon | 1 | 2005 | 1707 | 0.040 |
Why?
|
| Combined Modality Therapy | 1 | 2011 | 8540 | 0.040 |
Why?
|
| Disease | 1 | 2004 | 675 | 0.040 |
Why?
|
| Patient Selection | 1 | 2011 | 4252 | 0.040 |
Why?
|
| Caffeine | 1 | 2003 | 702 | 0.040 |
Why?
|
| Research Personnel | 1 | 2023 | 589 | 0.040 |
Why?
|
| Health Surveys | 1 | 2008 | 4055 | 0.040 |
Why?
|
| Influenza Vaccines | 1 | 2004 | 780 | 0.030 |
Why?
|
| Research | 1 | 2004 | 1977 | 0.030 |
Why?
|
| Mental Recall | 1 | 2002 | 1218 | 0.030 |
Why?
|
| Central Nervous System Stimulants | 1 | 2003 | 1168 | 0.030 |
Why?
|
| Age of Onset | 1 | 2001 | 3342 | 0.030 |
Why?
|
| Aspirin | 1 | 2006 | 3135 | 0.030 |
Why?
|
| Genome-Wide Association Study | 1 | 2013 | 12806 | 0.030 |
Why?
|
| Consensus | 1 | 2023 | 3208 | 0.030 |
Why?
|
| Reproducibility of Results | 1 | 2011 | 20144 | 0.030 |
Why?
|
| Survival Analysis | 1 | 2005 | 10100 | 0.030 |
Why?
|
| Models, Theoretical | 1 | 2004 | 3561 | 0.030 |
Why?
|
| Follow-Up Studies | 2 | 2003 | 39309 | 0.020 |
Why?
|
| Alleles | 1 | 2002 | 6895 | 0.020 |
Why?
|
| Computer Simulation | 1 | 2024 | 6259 | 0.020 |
Why?
|
| Clinical Trials as Topic | 1 | 2006 | 8045 | 0.020 |
Why?
|
| Mortality | 1 | 2001 | 2910 | 0.020 |
Why?
|
| Smoking Cessation | 1 | 2001 | 2085 | 0.020 |
Why?
|
| Sex Factors | 1 | 2003 | 10619 | 0.020 |
Why?
|
| Environmental Exposure | 1 | 2004 | 4554 | 0.020 |
Why?
|
| Health Personnel | 1 | 2002 | 3384 | 0.020 |
Why?
|
| Genotype | 1 | 2002 | 13036 | 0.020 |
Why?
|
| Prognosis | 1 | 2006 | 29948 | 0.020 |
Why?
|
| Young Adult | 1 | 2011 | 59939 | 0.010 |
Why?
|
| Adolescent | 1 | 2011 | 88904 | 0.010 |
Why?
|
| Infant, Newborn | 1 | 2002 | 26389 | 0.010 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2002 | 18075 | 0.010 |
Why?
|
| Pregnancy | 1 | 2002 | 30237 | 0.010 |
Why?
|